Bone morphogenetic proteins in melanoma: Angel or devil?

Cancer and Metastasis Reviews

Volumn 24, Issue 2, 2005, Pages 251-263

  Hsu, Mei Yu ^a   Rovinsky, Sherry ^a   Penmatcha, Sunita ^a,b   Herlyn, Meenhard ^c   Muirhead, DesiRae ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Carcinogenesis; Noggin; Smad; Transforming growth factor ; Tumor progression

Indexed keywords

BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CHEMOTAXIS; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; HUMAN; LABORATORY TEST; MELANOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOTAXIS; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 21644447413     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-005-1575-y     Document Type: Review

References (80)

1. Balemans W, Van Hul W: Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol 250: 231-250, 2002
2. Miyazono K, Kusanagi K, Inoue H: Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187: 265-276, 2001
3. von Bubnoff A, Cho KW: Intracellular BMP signaling regulation in vertebrates: Pathway or network? Dev Biol 239: 1-14, 2001
4. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P: The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277: 5330-5338, 2002
5. Hassel S, Schmitt S, Hartung A, Roth M, Nohe A, Petersen N, Ehrlich M, Henis YI, Sebald W, Knaus P: Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am 85-A Suppl 3: 44-51, 2003
6. Laurikkala J, Kassai Y, Pakkasjarvi L, Thesleff I, Itoh N: Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev Biol 264: 91-105, 2003
7. Canalis E, Economides AN, Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24: 218-235, 2003
8. Zwijsen A, Verschueren K, Huylebroeck D: New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett 546: 133-139, 2003
9. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, Niehrs C: Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401: 480-485, 1999
10. Whitman M: Smads and early developmental signaling by the TGF-beta superfamily. Genes Dev 12: 2445-2462, 1998
11. Botchkarev VA, Botchkareva NV, Sharov AA, Funa K, Huber O, Gilchrest BA: Modulation of BMP signaling by noggin is required for induction of the secondary (nontylotrich) hair follicles. J Invest Dermatol 118: 3-10, 2002
12. Zhang H, Bradley A: Mice deficient for BMP2 are non-viable and have defects in amnion/chorion and cardiac development. Development 122: 2977-2986, 1996
13. Winnier G, Blessing M, Labosky PA, Hogan BL: Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev 9: 2105-2116, 1995
14. Blessing M, Schirmacher P, Kaiser S: Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: Inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 135: 227-239, 1996
15. Botchkarev VA, Botchkareva NV, Roth W, Nakamura M, Chen LH, Herzog W, Lindner G, McMahon JA, Peters C, Lauster R, McMahon AP, Paus R: Noggin is a mesenchymally derived stimulator of hair-follicle induction. Nat Cell Biol 1: 158-164, 1999
16. Mabie PC, Mehler MF, Kessler JA: Multiple roles of bone morphogenetic protein signaling in the regulation of cortical cell number and phenotype. J Neurosci 19: 7077-7088, 1999
17. McMahon JA, Takada S, Zimmerman LB, Fan CM, Harland RM, McMahon AP: Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev 12: 1438-1452, 1998
18. Graff JM: Embryonic patterning: to BMP or not to BMP, that is the question. Cell 89: 171-174, 1997
19. Merino R, Rodriguez-Leon J, Macias D, Ganan Y, Economides AN, Hurle JM: The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 126: 5515-5522, 1999
20. De Bosscher K, Hill CS, Nicolas FJ: Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J 379: 209-216, 2004
21. Zhou XR Woodford-Richens K, Lehtonen R, Kurose K, Aldred M, Hampel H, Launonen V, Virta S, Pilarski R, Salovaara R, Bodmer WF, Conrad BA, Dunlop M, Hodgson SV, Iwama T, Jarvinen H, Kellokumpu I, Kim JC, Leggett B, Markie D, Mecklin JP, Neale K, Phillips R, Piris J, Rozen P, Houlston RS, Aaltonen LA, Tomlinson IP, Eng C: Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet 69: 704-711, 2001
22. Hsu MY, Elder DE, Herlyn M: The Wistar melanoma (WM) cell lines. In: Masters JRW, Palsson B (eds) Human Cell Culture. Kluwer Academic Publishers, Nowell, MA, 1999, pp 259-274
23. Seftor EA, Seftor REB, Hendrix MJC: Selection of invasive and metastatic subpopulation from a heterogeneous human melanoma cell line. BioTechniques 9: 324-331, 1990
24. Hendrix MJC, Seftor EA, Seftor EB, Fidler IJ: A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 38: 137-147, 1987
25. Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC, Leung KM: Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol 37: 225-233, 2001
26. Thomas BG, Hamdy FC: Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 3: 283-285, 2000
27. De Pinieux G, Flam T, Zerbib M, Taupin P, Bellahcene A, Waltregny D, Vieillefond A, Poupon MF: Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: A clinicopathological and immunohistochemical study of 43 cases. J Urol 166: 1924-1930, 2001
28. Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS, Yamanaka H: Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268-274, 2003
29. Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K, Clement JH: Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 23: 89-95, 2003
30. Higinbotham KG, Karavanova ID, Diwan BA, Perantoni AO: Deficient expression of mRNA for the putative inductive factor bone morphogenetic protein-7 in chemically initiated rat nephroblastomas. Mol Carcinog 23: 53-61, 1998
31. Raida M, Sarbia M, Clement JH, Adam S, Gabbert HE, Hoffken K: Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer 83: 38-44, 1999
32. Blessing M, Nanney LB, King LE, Hogan BL: Chemical skin carcinogenesis is prevented in mice by the induced expression of a TGF-beta related transgene. Teratog Carcinog Mutagen 15: 11-21, 1995
33. Wach S, Schirmacher P, Protschka M, Blessing M: Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene 20: 7761-7769, 2001
34. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW, Korc M: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 1202-1216, 1999
35. Yamada N, Kato M, ten Dijke P, Yamashita H, Sampath TK, Heldin CH, Miyazono K, Funa K: Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. Br J Cancer 73: 624-629, 1996
36. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA: Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60: 2840-2844, 2000
37. Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA, Kim SJ: Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9: 6046-6051, 2003
38. Zavadil J, Brezinova J, Svoboda P, Zemanova Z, Michalova K: Smad5, a tumor suppressor candidate at 5q31.1, is hemizygously lost and not mutated in the retained allele in human leukemia cell line HL60. Leukemia 11: 1187-1192, 1997
39. Cheng KH, Ponte JF, Thiagalingam S: Elucidation of epigenetic inactivation of SMAD8 in cancer using targeted expressed gene display. Cancer Res 64: 1639-1646, 2004
40. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D: Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 22: 4889-4897, 2003
41. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M: Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 9: 302-312, 2003
42. Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J, Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201: 238-249, 2003
43. Liu FS, Chen JT, Hsieh YT, Ho ES, Hung MJ, Lu CH, Chiou LC: Loss of Smad4 protein expression occurs infrequently in endometrial carcinomas. Int J Gynecol Pathol 22: 347-352, 2003
44. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996
45. Natsugoe S, Xiangming C, Matsumoto M, Okumura H, Nakashima S, Sakita H, Ishigami S, Baba M, Takao S, Aikou T: Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus. Clin Cancer Res 8: 1838-1842, 2002
46. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET: Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26: 516-521, 2003
47. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C: SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 104: 446-449, 2003
48. Franceschi RT, Wang D, Krebsbach PH, Rutherfold RB: Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 78: 476-486, 2000
49. Andrews PW, Damjanov I, Berends J, Kumpf S, Zappavigna V, Mavilio F, Sampath K: Inhibition of proliferation and induction of differentiation of pluripotent human embryonal carcinoma cells by osteogenic protein-1 (or bone morphogenetic protein-7). Lab Invest 71: 243-251, 1994
50. Maliakal JC, Asahina I, Hauschka PV, Sampath TK: Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. Growth Factors 11: 227-234, 1994
51. Franzen A, Heldin NE: BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285: 773-781, 2001
52. Hardwick JC, Van Den Brink GR, Bleuming SA, Ballester I, Van Den Brande JM, Keller JJ, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP: Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126: 111-121, 2004
53. Reinholz MM, Iturria SJ, Ingle JN, Roche PC: Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: Analysis by real-time quantitative PCR. Breast Cancer Res Treat 74: 255-269, 2002
54. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD, Izbicka E: Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9: 327-331, 1998
55. Wen XZ, Miyake S, Akiyama Y, Yuasa Y: BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 316: 100-106, 2004
56. Brubaker KD, Corey E, Brown LG, Vessella RL: Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91: 151-160, 2004
57. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J: Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497: 186-196, 2000
58. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh Choudhury G: Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272: 705-711, 2000
59. Dumont N, Arteaga CL: A kinase-inactive type II TGF-beta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 301: 108-112, 2003
60. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454, 2003
61. Katoh M, Terada M: Overexpression of bone morphogenic protein (BMP)-4 mRNA in gastric cancer cell lines of poorly differentiated type. J Gastroenterol 31: 137-139, 1996
62. Buckley S, Shi W, Driscoll B, Ferrario A, Anderson K, Warburton D: BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 286: L81-86, 2004
63. Langenfeld EM, Langenfeld J: Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2: 141-149, 2004
64. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57: 5022-5027, 1997
65. Medrano EE: Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 22: 3123-3129, 2003
66. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H: High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 62: 7162-7165, 2002
67. Saikali Z, Sinnett D: Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 89: 418-422, 2000
68. Lage H, Dietel M, Froschle G, Reymann A: Expression of the novel mitoxantrone resistance associated gene MXR7 in colorectal malignancies. Int J Clin Pharmacol Ther 36: 58-60, 1998
69. Hsu HC, Cheng W, Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 57: 5179-5184, 1997
70. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Buchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564, 2001
71. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103: 455-465, 2003
72. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M: Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 61: 8306-8316, 2001
73. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001
74. Akhurst RJ: TGF-beta antagonists: Why suppress a tumor suppressor? J Clin Invest 109: 1533-1536, 2002
75. Wakefield LM, Roberts AB: TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22-29, 2002
76. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET: Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64: 994-999, 2004
77. Wang SN, Lapage J, Hirschberg R: Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12: 2392-2399, 2001
78. Fu SC, Wong YP, Chan BP, Pau HM, Cheuk YC, Lee KM, Chan KM: The roles of bone morphogenetic protein (BMP) 12 in stimulating the proliferation and matrix production of human patellar tendon fibroblasts. Life Sci 72: 2965-2974, 2003
79. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM: BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9: 1033-1038, 2003
80. van der Poel HG, Hanrahan C, Zhong H, Simons JW: Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30: 380-386, 2003